Human Insulin Market 2024 Growth Opportunities, Driving Factors by Manufacturers- Novo Nordisk, Sanofi A/S, Eli Lilly & Company, and Astra Zeneca PLC

Insulin is a peptide hormone that helps in controlling the absorption of fat and carbohydrate in the body. The human insulin market is anticipated to grow at a robust CAGR during the forecast period due to a high incidence rate of diabetes, globally.
The growth in the prevalence rate of diabetes, changes in lifestyles, rising number of obese patients, and increasing geriatric population are the major factors driving the market growth. However, the high cost for the development and production of insulin, manufacturing complexities, and stringent regulatory scenario for the approval of derived products are hampering the growth of the market. The development of pipeline insulin products and expiry of key patents are providing an opportunity for the manufacturers of human insulin.

Top Manufacturer Detail:

Novo Nordisk, Sanofi A/S, Eli Lilly & Company, and Astra Zeneca PLC are the key players in the market. The other prominent players in the market include Biocon, Julphar, Wockhardt, GSK, Oramed, and SemBioSys Genetics.

Free| Request Sample Copy is Available:

Global Human Insulin market is estimated to witness a CAGR of 10.2% during the forecast period 2017-2023. The human insulin market is analyzed based on three segments-top insulin brands, product types, and regions.

The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the global human insulin market, followed by Europe, Asia Pacific, and Rest of the World. Nearly half of the market is occupied by North America, with the US being the major contributor to the market growth.

Based on types, the market is segmented into modern human insulin and traditional human insulin. Modern human insulin includes rapid-acting insulin analogs, premixed analogue insulins, and long-acting insulin. Traditional human insulin includes regular human insulin, NPH human insulin, and pre-mixed insulin. Novo Nordisk holds 45.0% share of the total modern insulin market.

Browse Complete Report:

Table of Contents 

1 Industry Outlook 8
1.1 Industry Overview 8
1.2 Total Addressable Market 8
1.3 Industry Trends 10

2 Report Outline 11
2.1 Report Scope 11
2.2 Report Summary 11
2.3 Research Methodology 12
2.4 Report Assumptions 12

3 Market Snapshot 13
3.1 Market Definition-Infoholic Research 13
3.2 Segmented Addressable Market (SAM) 13
3.2.1 Trends of Human Insulin market 14
3.3 Related Markets 15
3.3.1 Oncology (Cancer) Drugs 15
3.3.2 Active pharmaceutical ingredients (APIs) 16
3.3.3 Over the counter drugs (OTC) 16
3.3.4 Diabetes Drugs 17

4 Market Outline 18
4.1 Pipeline products 18
4.2 Market Segmentation 18
4.3 Porter 5(Five) Forces 19
4.4 PEST Analysis 20

5 Market Characteristics 21
5.1 Market Dynamics 22
5.1.1 Drivers 22 Increasing Aging Population 22 Increasing People Suffering with Diabetes 24
5.1.2 Opportunities 24 Increase healthcare spending 24 Patent Expiry for Blockbuster Drugs 25
5.1.3 Restraints 25 Complex regulatory process 25 High cost of insulin 25
5.1.4 DRO-Impact Analysis 27
5.1.5 Key Stakeholders 28

6 Insulin Types: Market Size and Analysis 29
6.1 Overview 29
6.2 Lantus 29
6.3 Humulin 29
6.4 Levemir 30
6.5 Humalog 30
6.6 NovoLog/NovoRapid 30
6.7 Tresiba 31
6.8 Basaglar/ Abasaglar 31
6.9 Toujeo 31
6.10 Apidra 32

7 Types: Market Size and Analysis 33
7.1 Overview 33
7.2 Modern Insulin 34
7.2.1 Rapid Acting Insulin Analogs 34
7.2.2 Premixed analogue insulins 34
7.2.3 Long-acting insulin 34
7.3 Traditional Human Insulin 35
7.3.1 Regular Human Insulin 35
7.3.2 NPH Human Insulin 36
7.3.3 Pre-Mixed Insulin 36

Place Direct Purchase order For Complete report:

Contact us:

Phone : +1-646-491-9876

E-Mail : [email protected]

Posted by on Thursday July 19 2018, 2:10 AM EDT. All trademarks acknowledged. Filed under Biotechnology, Diagnostics, Healthcare, Life Sciences, Medical Devices, Pharmaceuticals. Comments and Trackbacks closed. Follow responses: RSS 2.0

Comments are closed

News Categories

Featured Press Releases

Log in